Tenax Therapeutics

TENX Rare disease Lead: Phase 3 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-10

Catalyst timeline

TNX-103 enrollment doneend of 2027TNX-103 enrollment done, end of 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

levosimendan

TNX-103

Small Molecule Target: K-ATP channels, troponin C

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction Phase 3 oral Orion NCT05983250

levosimendan

TNX-102

Small Molecule

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction subcutaneous Orion

Discontinued (1)

imatinib — Pulmonary Arterial Hypertension · deprioritized the planned Phase 3 clinical trial of imatinib; no significant imatinib development activities ongoing

Biotech Distilled coverage (7)

2026-09-09 UPDATE: Tenax Therapeutics (TENX) - Fidelity Left, ADAR1 Arrived 🔒 Paid
2026-08-31 UPDATE: Tenax Therapeutics (TENX) - Munich Answered the Question I Asked 🔒 Paid
2026-08-11 UPDATE: Tenax Therapeutics (TENX) - The Coin Landed Tails
2026-07-31 UPDATE: Tenax Therapeutics (TENX) - The 2030 Cliff Just Moved to 2035 🔒 Paid
2026-07-08 UPDATE: Tenax Therapeutics (TENX) - Fidelity Shows Up at 14.9% 🔒 Paid
2026-07-02 Tenax Therapeutics (TENX) — Scientific Deep Dive for TNX-103 and Pipeline Products 🔒 Paid
2026-07-02 UPDATE: Tenax Therapeutics (TENX) - The Clock Just Got a Date on It 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.